LIPID LOWERING EFFECT OF ANTIDIABETIC DRUGS IN TYPE 2 DIABETES MELLITUS PATIENTS

Diabetes mellitus (DM), a common endocrine metabolic disorder, is an important cause of morbidity and mortality worldwide. Development of diabetes involves several pathogenic processes ranging from autoimmune destruction of the βcells of the pancreas with consequent insulin deficiency to abnormalities that result in resistance to insulin action. Diabetic dyslipidemia is frequently diagnosed in diabetes mellitus, which is characterized by elevated plasma levels of triglycerides, low-density lipoprotein cholesterol (LDL-C) and decreased levels of high-density lipoprotein cholesterol (HDL-C). Diabetic dyslipidemia complicates the management of diabetes mellitus and its complications like cardiovascular, renal disorders, etc. Totally 30 subjects were studied and out of 30 subjects, 15 subjects satisfied the study criteria, and were divided into two groups - 8 patients were in Metformin (group I), 7 patients were in Metformin+ Glimepiride (group II). The random venous blood sample was taken and analyzed for blood glucose levels and lipid profiles in both groups. The results showed the efficacy of the administration of combination of metformin and glimepiride simultaneously and metformin as monotherapy. There were significant changes in triglycerides, LDL, total cholesterol and HDL during the study period. The results of the present study have demonstrated that the addition of glimepiride to metformin in type 2 diabetes have beneficial effects on lipid profiles in addition to improved glycemic control throughout the study periodtion.